39,400 Shares in Neumora Therapeutics, Inc. $NMRA Acquired by Catalyst Funds Management Pty Ltd

Catalyst Funds Management Pty Ltd bought a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 2nd quarter, HoldingsChannel.com reports. The fund bought 39,400 shares of the company’s stock, valued at approximately $29,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cerity Partners LLC grew its holdings in shares of Neumora Therapeutics by 24.0% during the 1st quarter. Cerity Partners LLC now owns 302,505 shares of the company’s stock worth $303,000 after purchasing an additional 58,597 shares during the period. CWM LLC lifted its position in Neumora Therapeutics by 7,124.4% in the first quarter. CWM LLC now owns 25,213 shares of the company’s stock valued at $25,000 after buying an additional 24,864 shares during the last quarter. Federated Hermes Inc. purchased a new position in Neumora Therapeutics during the first quarter worth about $285,000. XTX Topco Ltd increased its position in shares of Neumora Therapeutics by 969.7% during the first quarter. XTX Topco Ltd now owns 233,597 shares of the company’s stock valued at $234,000 after acquiring an additional 211,759 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Neumora Therapeutics by 151.1% during the first quarter. Invesco Ltd. now owns 123,655 shares of the company’s stock valued at $124,000 after acquiring an additional 74,406 shares during the last quarter. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Stock Down 1.3%

Neumora Therapeutics stock opened at $2.33 on Friday. The firm has a market capitalization of $389.32 million, a P/E ratio of -1.59 and a beta of 2.98. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics, Inc. has a twelve month low of $0.61 and a twelve month high of $11.57. The stock’s fifty day simple moving average is $2.16 and its 200-day simple moving average is $1.56.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, equities analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. Needham & Company LLC upped their price target on Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Guggenheim upgraded Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lowered Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $7.57.

Insider Transactions at Neumora Therapeutics

In other news, major shareholder Arch Venture Partners Xii, Llc bought 1,915,700 shares of the business’s stock in a transaction that occurred on Monday, October 27th. The shares were purchased at an average cost of $2.61 per share, for a total transaction of $4,999,977.00. Following the completion of the purchase, the insider owned 6,046,907 shares of the company’s stock, valued at approximately $15,782,427.27. This represents a 46.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kristina Burow bought 1,915,700 shares of Neumora Therapeutics stock in a transaction that occurred on Monday, October 27th. The stock was purchased at an average cost of $2.61 per share, for a total transaction of $4,999,977.00. Following the acquisition, the director owned 6,046,907 shares of the company’s stock, valued at $15,782,427.27. This represents a 46.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 26.80% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.